The CHMP renders a positive opinion recommending approval for BIIB and Eisai's Leqembi for treating early Alzheimer's disease ...

TOKYO, Nov 15, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Japan Ltd announced today that a TV commercial will be ...

If the European Commission decides to grant sales of the medicine, it will be the first Alzheimer's medicine available in the ...

Eisai serves as the lead for lecanemab&CloseCurlyQuote ... we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our ...

Europe's medicines watchdog on Thursday partially approved a marketing request for a long-awaited new treatment for Alzheimer ...

Azurity Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved Danziten™, the first and only nilotinib with no mealtime restrictions indicated for adult patients ...

Most discontinued anti-tau antibodies (red) targeted tau’s N-terminus. Of the antibodies currently in trials (green), bepranemab and E2814 presented results at CTAD, while JJ-63733657/posdinemab and ...

at 13:29 Eisai Receives Positive Opinion from the CHMP in the European ... received Health Canada approval of its revyvetm Antimicrobial Wound Gel as a Class 2 Medical Device. This approval allows the ...

The European Medicines Agency re-examined clinical data of a subset of patients with one or no copies of the APOE4 gene ...

It has been a shaky time for healthcare stocks, but that only presents a buying opportunity. The Health Care Select Sector ...

A multitude of genes have been linked to the development of Alzheimer's disease. Specifically how those genes might influence ...

Report with market evolution powered by AI - The global wound care market size is estimated to grow by USD 6.95 billion from ...